Angiogenesis inhibitors combined with chemotherapy improve progression-free survival in advanced breast cancer patientsAdding angiogenesis inhibitors to chemotherapy helps advanced breast cancer patients stay disease-free longer

Clinical trial registrationGlobally, breast cancer is the most common malignancy in women. Despite treatment advances, 20–30% of early-stage patients progress to advanced disease, which remains largely incurable with a 5-year survival rate of only ~20%. Chemotherapy, the current mainstay, has reached a therapeutic plateau, with limited efficacy and potential pro-metastatic effects. Anti-angiogenic agents targeting VEGF/VEGFR2 (e.g., bevacizumab, TKIs) are used clinically, but their benefit in advanced breast cancer is controversial: progression-free survival (PFS) gains are inconsistent, overall survival (OS) benefits are unclear, and resistance with class-specific toxicities (e.g., hypertension) is common. Furthermore, comparative efficacy across drug classes and optimal patient selection remain undefined. These unresolved issues highlight the urgent need for a comprehensive synthesis to guide clinical decisions and future research.MethodsSystematic search of PubMed/Web of Science (up to July 16, 2025) identified 29 phase II/III RCTs (N = 8,480) comparing angiogenesis inhibitors + chemotherapy vs. chemotherapy alone (± placebo) in advanced breast cancer. Outcomes included PFS, OS, objective response rate (ORR), clinical benefit rate (CBR), disease control rate (DCR), and safety. Two independent reviewers performed screening, extraction, and quality assessment. Pooled HRs (95% CI) for PFS/OS; ORs for binary outcomes. Random-effects model used if I² ≥ 50%; prespecified subgroup/sensitivity analyses explored heterogeneity.ResultsThis meta-analysis (29 RCTs, N = 11,068) showed that adding angiogenesis inhibitors in advanced breast cancer significantly improved PFS (HR 0.75), ORR, CBR, and DCR (all P